Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
Launched by GLAXOSMITHKLINE · Sep 8, 2005
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ICU patients with an expected duration of mechanical ventilation for 2 to 3 days and requiring analgesia and sedation.
- Exclusion criteria:
- • ICU patients resuscitated in the previous 24 hours, neurotrauma or expecting major surgery, not likely to survive of with limit care status.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ede, , Netherlands
Eindhoven, , Netherlands
Hengelo, , Netherlands
Amsterdam, , Netherlands
Apeldoorn, , Netherlands
Den Bosch, , Netherlands
Alkmaar, , Netherlands
Den Haag, , Netherlands
Zwolle, , Netherlands
Rotterdam, , Netherlands
Dordrecht, , Netherlands
Haarlem, , Netherlands
Helmond, , Netherlands
Tiel, , Netherlands
Venlo, , Netherlands
Patients applied
Trial Officials
GSK Clinical Trials, MD
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials